


Bases genéticas de las anomalías congénitas renales y del tracto urinario (CAKUT)

M. Nicole Bascur Postel


Teaching Course Nefrología Pediátrica
Valdivia 26 y 27 de septiembre 2019

Epidemiología CAKUT


- 20-30 % de todas las malformaciones
- 1 en 500 RNV
- Europa - 41,3 % de los niños con TRR
- Registro Chileno de ERC Pediátrica- 53% pacientes




Horseshoe kidney




Vesicoureteral reflux




Renal hypoplasia




Megaureter




Renal agenesis




Duplex collecting system





Multicystic dysplastic kidney




Posterior urethral valves







Inducción yema ureteral




Transición mesénquimo epitelial




Morfogénesis de la ramificación renal



Desarrollo y elongación de nefrones (nefrogénesis)




Inducción yema ureteral



Direct reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors

Michael M. Kaminski¹, Jelena Tomic^{1,2,3,4}, Catena Kresbach¹, Hannes Engel¹, Jonas Klockenbusch¹, Anna-Lena Müller¹, Roman Pichler¹, Florian Grahammer¹, Oliver Kretz^{1,5}, Tobias B. Huber^{1,6}, Gerd Walz^{1,6}, Sebastian J. Arnold^{1,2,6,7} and Soeren S. Lienkamp^{1,6,7}




Generación de células tubulares ex vivo

Emx2, Hnf1b, Hnf4a and Pax8

Copy-Number Disorders Are a Common Cause of Congenital Kidney Malformations



Simone Sanna-Cherchi,^{1,2} Krzysztof Kiryluk,¹ Katelyn E. Burgess,¹ Monica Bodria,³ Matthew G. Sampson,⁵ Dexter Hadley,⁴ Shannon N. Nees,¹ Miguel Verbitsky,¹ Brittany J. Perry,¹ Roel Sterken,¹ Vladimir J. Lozanovski,⁶ Anna Materna-Kiryluk,⁷ Cristina Barlassina,^{8,9} Akshata Kini,⁴ Valentina Corbani,¹⁰ Alba Carrea,³ Danio Somenzi,¹¹ Corrado Murtas,³ Nadica Ristoska-Bojkovska,⁶ Claudia Izzi,¹² Beatrice Bianco,¹¹ Marcin Zaniew,¹³ Hana Flogelova,¹⁴ Patricia L. Weng,¹ Nilgun Kacak,¹ Stefania Giberti,¹¹ Maddalena Gigante,¹⁵ Adela Arapovic,¹⁶ Kristina Drnasin,¹⁷ Gianluca Caridi,³ Simona Curioni,⁸ Franca Allegri,¹⁸ Anita Ammenti,¹⁹ Stefania Ferretti,²⁰ Vinicio Goj,²¹ Luca Bernardo,²¹ Vaidehi Jobanputra,²² Wendy K. Chung,²³ Richard P. Lifton,²⁴ Stephan Sanders,²⁴ Matthew State,²⁴ Lorraine N. Clark,²⁵ Marijan Saraga,^{16,26} Sandosh Padmanabhan,²⁷ Anna F. Dominiczak,²⁷ Tatiana Foroud,²⁸ Loreto Gesualdo,¹⁵ Zoran Gucev,⁶ Landino Allegri,¹¹ Anna Latos-Bielenska,⁷ Daniele Cusi,⁸ Francesco Scolari,¹² Velibor Tasic,⁶ Hakon Hakonarson,^{4,5} Gian Marco Ghiggeri,³ and Ali G. Gharavi^{1,*}



192 casos RHD (NA, Europa: Italia, Polonia, Macedonia, Croacia, República Checa)
4733 controles pareados por etnia


DNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation

Nicola Wanner,¹ Julia Vornweg,^{2,3} Alexander Combes,^{4,5} Sean Wilson,⁴ Julia Plappert,² Gesa Rafflenbeul,² Victor G. Puelles,¹ Raza-Ur Rahman,⁶ Timur Liwinski,^{6,7} Saskia Lindner,² Florian Grahammer,¹ Oliver Kretz,^{1,8} Mary E. Wlodek,⁹ Tania Romano,¹⁰ Karen M. Moritz,¹¹ Melanie Boerries,^{12,13,14} Hauke Busch,^{14,15} Stefan Bonn,^{6,16} Melissa H. Little,^{5,17} Wibke Bechtel-Walz,² and Tobias B. Huber^{1,2,18,19}



PAX2

- CAKUT aislado
- Displasia nervio óptico y malformaciones renales
- Autosómico dominante
- 10q24.31



Mutations in *PAX2* Associate with Adult-Onset FSGS

Moumita Barua,* Emilia Stellacci,[†] Lorenzo Stella,[‡] Astrid Weins,[§] Giulio Genovese,^{*||¶**} Valentina Muto,[†] Viviana Caputo,^{††} Hakan R. Toka,^{*‡‡} Victoria T. Charoonratana,^{*} Marco Tartaglia,[†] and Martin R. Pollak^{*}

176 familias GEFS
85 individuos CAKUT
SECUENCIACIÓN EXOMA,
Sanger

Table 2. Clinical features of FSGS families with *PAX2* mutation-associated disease

Family ID	Self-Reported Ethnicity	Ages at Disease Onset (yr)	Persons Affected (n)	Patients with ESRD (n)	Ages at Development of ESRD (yr)	Ultrasonography Findings	Diagnosis	Patients with Biopsy (n)
FG-BF	White	8	2	1	Unknown	Increased echogenicity	FSGS	1
FG-DO	African American	7–11	2	Unknown	Unknown	Unknown	Proteinuria	Unknown
FG-EQ	European	17–68	6	2	40, 58	Dilated renal pelvis, small kidneys	FSGS	2
FG-GE	Unknown	Unknown	2	1	Unknown	Slightly small kidney, calyceal diverticulum	Proteinuria	1
FG-IX	Middle Eastern	36	4	Unknown	Unknown	Unknown	FSGS	Unknown
FG-JO	East Indian	31–32	5	4	30–36	Unknown	FSGS	3
FG-KV	European American	15–24	3	1	42	Unknown	FSGS, undiagnosed PRS	3

Dominant *PAX2* mutations may cause steroid-resistant nephrotic syndrome and FSGS in children

Asaf Vivante^{1,2} · Orna Staretz Chacham³ · Shirlee Shril¹ · Ruth Schreiber⁴ · Shrikant M. Mane⁵ · Ben Pode-Shakked^{2,6} · Neveen A. Soliman⁷ · Irene Koneth⁸ · Mario Schiffer⁹ · Yair Anikster⁶ · Friedhelm Hildebrandt¹


Table 1 Four different heterozygous *PAX2* mutations detected in four different families with SRNS/FSGS


Family-Individual	Ancestry	Nucleotide alteration	Alteration in coding sequence ^a	Zygosity
AN10-21 (index family)	Arab	c.69-70InsG ^b	p.Val26Glyfs*28	Het
A4041-11	Egypt	c.254G>T	p.Gly85Val	Het
A4041-23	Egypt	c.254G>T	p.Gly85Val	Het
A4041-24	Egypt	c.254G>T	p.Gly85Val	Het
A5089-11	Europe	c.862-1G>A	Splice mutation	Het
A5089-21	Europe	c.862-1G>A ^c	Splice mutation	Het
A5281	Europe	c.275C>T	p.Thr92Met	Het

Family-Individual	SIFT/PP2	Presenting symptoms (age)	Renal histology	eGFR at presentation/ESRD age	Extra-renal phenotype
AN10-21 (index family)	Deleterious/1 (reported)	Elevated creatinine and proteinuria (2y)	FSGS	ESRD at age 4 years	Coloboma, cardiomyopathy, microcephaly
A4041-11	Deleterious/1 (novel)	Proteinuria and elevated creatinine (35y)	n/a	ESRD at age 39 years	–
A4041-23	Deleterious/1 (novel)	Proteinuria and elevated creatinine (13y)	FSGS	63 ml/min/1.73m ²	–
A4041-24	Deleterious/1 (novel)	Edema, proteinuria and elevated creatinine (10y)	FSGS	50 ml/min/1.73m ²	–
A5089-11	Obligatory splice ^b (novel)	Proteinuria and normal creatinine	n/a	n/a	–
A5089-21	Obligatory splice (novel)	Edema, proteinuria and elevated creatinine (20)	FSGS	ESRD at age 27	–
A5281	Deleterious/1 (novel)	HTN found on screening (18)	FSGS	n/a ^d	Cryptorchidism

HNF1B

- Displasia renal, especialmente quística
- Quistes renales y diabetes
- Nefropatía túbulo intersticial AD
- 17q12
- Autosómico dominante
- Deleción completa del gen 50%





***HNF1B* nephropathy has a slow-progressive phenotype in childhood—with the exception of very early onset cases: results of the German Multicenter *HNF1B* Childhood Registry**

Christine Okorn¹ · Anne Goertz¹ · Udo Vester¹ · Bodo B. Beck^{2,3} · Carsten Bergmann⁴ · Sandra Habbig⁵ · Jens König⁶ · Martin Konrad⁶ · Dominik Müller⁷ · Jun Oh⁸ · Nadina Ortiz-Brüchle⁹ · Ludwig Patzer¹⁰ · Raphael Schild⁸ · Tomas Seeman¹¹ · Hagen Staude¹² · Julia Thumfart⁷ · Burkhard Tönshoff¹³ · Ulrike Walden¹⁴ · Lutz Weber⁵ · Marcin Zaniew¹⁵ · Hildegard Zappel¹⁶ · Peter F. Hoyer¹ · Stefanie Weber¹⁷

62 pacientes con Nefropatía *HNF1B* con diagnóstico molecular




Table 3 Extrarenal manifestations at the end of observation (median age of the total cohort 8 years, mean 8.2 years)

Extrarenal manifestation	Patients	%	Age at diagnosis
Hypomagnesemia (< 0.65 mmol/l)	12/50	24	10.0 years (median)
Hyperuricemia	19/52	37	1.0 year (median)
Elevated liver enzymes	12/58	21	11.0 years (median)
Hyperglycemia	4/50	8	0, 4, 12, 14 years
Urogenital anomalies	1/62	2	Postnatal

Detección de mutaciones del gen de HNF1B en niños con malformaciones congénitas renales y del tracto urinario

Detection of mutations of the HNF1B gene in children with congenital anomalies of the kidney and urinary tract

M. Nicole Bascur P.^a, M. Luisa Ceballos O.^b, Mauricio Farfán U.^b, Iván Gajardo H.^b y Joaquín López C.^b




Figura 1. Caracterización de la muestra de acuerdo a tipo de Malformación Nefrourológica.




Figura 2. Caracterización de la muestra de acuerdo a la Etapa de Enfermedad Renal Crónica.

Tabla 1. Características generales de los casos índices

ID paciente	Edad (a)	Sexo	CAKUT	Etapa ERC	Exon	Mutación
10	17	F	Displasia quística izquierda	1	4	C1027T
24	8	M	Displasia no quística bilateral	5	4	C1027T

Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract

Amelie T. van der Ven, Dervla M. Connaughton, [...], and Friedhelm Hildebrandt

(A) Causative mutation in a **known/syndromic CAKUT gene** (29/232; 13%)

(B) Causative mutation in a **phenocopy gene** (3/232; 1%)

(C) Candidate **syndromic CAKUT gene** in a patient with isolated CAKUT (15/232; 6%)

(D) **Murine CAKUT gene** (5/232; 2%)


(E) **Novel, single candidate gene** (19/232; 8%)

(F) **Novel, multiple candidate genes per family** (22/232; 10%)

(G) **Disease-causing mutation in non-CAKUT gene** (10/232; 4%)

n=232 families with CAKUT
(note that 9 families had findings in 2 categories)

(H) **No mutation detected** (129/232; 56%)



232 fam CAKUT

Whole-Exome Sequencing in the molecular diagnosis of individuals with congenital anomalies of kidney and urinary tract and identification of a new causative gene

Mir Reza Bekheirnia, MD, FACMG^{1,2,3,4}, Nasim Bekheirnia, MBS, MS^{1,2,4}, Matthew N. Bainbridge, PhD⁵, Shen Gu, PhD¹, Zeynep Hande Coban Akdemir, PhD¹, Tomek Gambin, PhD¹, Nicolette K. Janzen, MD^{3,4}, Shalini N. Jhangiani, MS⁵, Donna M. Muzny, MS⁵, Mini Michael, MD^{4,6}, Eileen D. Brewer, MD^{4,6}, Ewa Elenberg, MD^{4,6}, Arundhati S. Kale, MD^{4,6}, Alyssa A. Riley, MD^{4,6}, Sarah J. Swartz, MD^{4,6}, Daryl A. Scott, MD, PhD^{1,4}, Yaping Yang, PhD¹, Poyyapakkam R. Srivaths, MD^{4,6}, Scott E. Wenderfer, MD, PhD^{4,6}, Joann Bodurtha, MD, MPH⁷, Carolyn D. Applegate, MS⁷, Milen Velinov, MD, PhD⁸, Angela Myers, MD⁹, Lior Borovik, MS⁹, William J. Craigen, MD, PhD^{1,4}, Neil A. Hanchard, MD, PhD^{1,4}, Jill A. Rosenfeld, MS¹, Richard Alan Lewis, MD^{1,4,10}, Edmond T. Gonzales, MD^{3,4}, Richard A. Gibbs, PhD^{1,5}, John W. Belmont, MD, PhD^{1,4}, David R. Roth, MD^{3,4}, Christine Eng, MD¹, Michael C. Braun, MD^{4,6}, James R. Lupski, MD, PhD^{1,4,5,11}, and Dolores J. Lamb, PhD^{2,3,12}

62 familias
CAKUT
5% fam SNVs:
PAX2, HNF1B,
EYA1
4 fam CNV
patogénicas

Family ID	Gene	Sex	Ethnicity	Renal phenotype	Genome build	Chr: position	Nucleotide change	Amino-acid change	Other organ defects
1	<i>PAX2</i>	M,F	Spanish	RHD	Hg19	10: 102509528	c.70delG	p.G24fs	Optic nerve coloboma (previously undiagnosed)
2	<i>HNF1B</i>	M	Mixed Cmcnsian and African Caribbean	CRD	Hg19	17: 36070584	c.1132dupC	p.Q378fs	Gout, elevated LFTs (recent diagnosis) and increased echogenicity of pancreas (not noted prior to WES)
3	<i>EYA1</i>	F	AA	VUR, MCDK	Hg19	8: 72183988	c.867+5G>A	n/a	No

AA African American; AD, autosomal dominant, BOR; Branchio-oto-renal syndrome; CADD, Combined Annotation Dependent Depletion; Chr, chromosome; Exome Aggregation Consortium; LFT, liver function tests; LOF, loss-of-function; MCDK, Multicystic dysplastic kidney; N/R, none reported, RHD, Renal

Copy-number variants (CNVs) identified (from WES data of 62 families) which are relevant to the patient's phenotype

Family ID	Chromosomal region	CNV Type	Start (Mb)	End (Mb)	Size (Mb)	Number of genes	Syndrome	Phenotype	Parental Studies	Comments
Family 34	22q11	Trp	16.63	18.64	2.01	33	Cat eye syndrome	VUR, further details in text (multiple anomalies)	<i>De Novo</i>	Pathogenic
Family 39	16p13.11	Dup	15.12	16.29	1.17	19	16p13.11 dup	MCDK, facial dysmorphic features	Unknown	Pathogenic
Family 10	16p11.2	Dup	29.68	30.20	0.52	35	16p11.2 dup	Solitary kidney, psychiatric disorder, hypothyroidism	Unknown	Pathogenic
Family 31	16p11.2	Del	28.83	29.04	0.21	13	16p11.2 del	VUR, seizure, DD, LD, and optic edema	Unknown	Pathogenic
Family 33	3q29	Dup	197.51	197.59	0.08	2	-	VUR, cataract, and growth delay	Unknown	VUS
Family 25	2p24.3	Del	15.30	15.38	0.08	1	-	PUV, heterotaxy	Inherited	VUS
Family 21	4q35.1	Dup	185.99	189.11	3.12	30	-	PUV	Inherited	VUS

DD, developmental delay; **del**, deletion; **dup**, duplication; **LD**, learning disability; **MCDK**, multicystic dysplastic kidney; **PUV**, posterior urethral valve; **trp**, triplication; **VUR**, vesicoureteral reflux; **VUS**, variant of uncertain clinical significance

¿Por qué hacer estudios genéticos en pacientes con CAKUT?

- Confirma diagnóstico clínico
- Acelera evaluación de manifestaciones extra renales
- Establece patrones de herencia
- Determinación de tratamientos
- Guía decisiones en el planeamiento familiar
- Identifica factores de riesgo de recurrencia en postTx
- Evaluación de miembros de la familia como donantes renales

- ¿ A quienes ?
- Sociedades científicas
- Cambios paradigmas, medicina individualizada, etiológica



Gracias

